MergerOct 15, 2026, 04:16 PM
Supernus Pharmaceuticals Stockholders Approve Merger With Indivior
AI Summary
Supernus Pharmaceuticals, Inc. held a special meeting of its stockholders on October 15, 2026, where the adoption of the Merger Agreement with Indivior Pharmaceuticals Inc. and Artemis Merger Sub, Inc. was overwhelmingly approved. The merger will result in Supernus becoming a wholly-owned subsidiary of Indivior. Stockholders also approved, on a non-binding basis, the compensation for named executive officers in connection with the Merger.
Key Highlights
- Supernus Pharmaceuticals stockholders approved the Merger Agreement with Indivior Pharmaceuticals Inc. and Artemis Merger Sub, Inc.
- Proposal 1: Adoption of the Merger Agreement received 48,249,532 'For' votes, 235,601 'Against', and 67,004 'Abstain'.
- Proposal 2: Approval of executive compensation related to the Merger passed with 32,688,410 'For' votes, 15,847,350 'Against', and 16,377 'Abstain'.
Price Impact
More from SUPN